[A26-59] Blinatumomab (B-ALL, 1st and 2nd complete remission) – Benefit assessment according to §35a Social Code Book V

Last updated 01.09.2026

Project no.:
A26-59

Commission:
Commission awarded on 29.05.2026 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adults with Philadelphia chromosome-negative CD19+ B-cell precursor acute lymphoblastic leukaemia

Result of dossier assessment:

Patients in first complete remission with MRD of at least 0.1%: added benefit not proven
Patients in second complete remission with MRD of at least 0.1%: added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://doi.org/10.60584/A26-59

Project no.	Title	Status
G15-15	Blinatumomab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V	Commission completed
G17-04	Blinatumomab (acute lymphoblastic leukaemia)- Assessment according to §35a (para. 1., sentence 10) Social Code Book V (expiry of the decision)	Commission completed
G19-07	Blinatumomab (ALL, paediatric patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V	Commission completed
G19-08	Blinatumomab (ALL, MRD-positive patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V	Commission completed
G21-23	Blinatumomab (acute lymphoblastic leukaemia, Ph-, CD19+, children aged 1 to 18 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V	Commission completed
G21-04	Blinatumomab (acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V	Commission completed
G25-07	Blinatumomab (refractory ALL, children < 1 year) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V	Commission completed
G25-08	Blinatumomab (first relapsed ALL, children < 1 year) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V	Commission completed
A26-57	Blinatumomab (B-ALL, relapsed or refractory) – Benefit assessment according to §35a Social Code Book V	Commission completed
A26-58	Blinatumomab (B-ALL, refractory or relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V	Commission completed
A26-61	Blinatumomab (B-ALL, newly diagnosed, consolidation therapy) – Benefit assessment according to §35a Social Code Book V	Commission completed
A26-60	Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Benefit assessment according to §35a Social Code Book V	Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form